Pimozide, a first-generation antipsychotic drug used to treat Tourette syndrome and treatment-resistant tics, has been shown to inhibit STAT5 in myelogenous leukemia [21], osteosarcoma [22], and GBM [13] cells in vitro. This evidence concerns the gene STAT5A and myeloid leukemia.